Viral Vector
CDMO Services
From design to GMP delivery
Welcome to
Minaris Viral Vectors
With over 10 years of viral vector manufacturing experience, Minaris Viral Vectors helps innovators advance in vivo and ex vivo viral vector programs from plasmid and vector design through process development, GMP manufacturing, integrated testing, release, and fill-finish.
Vectors are manufactured in Philadelphia, the Minaris Viral Vectors Center of Excellence, where proven GMP execution, scalable manufacturing capabilities, integrated testing, and OXGENE technologies help reduce bottlenecks and accelerate complex programs from construct to clinic.
80+ GMP viral vector batches delivered across ex vivo and in vivo programs
Integrated PD, GMP manufacturing, testing, and lot release capabilities to streamline development and reduce handoffs
Differentiated OXGENE technologies, including TESSA®, XOFLX®, a clonal HEK293 cell line, and plasmid solutions designed to improve yield, quality, and COGs versus traditional approaches
Grade B CERs that can accommodate aseptic processing and may help reduce downstream losses
Flexible workflows supporting client-owned processes or access to established Minaris solutions
Delivering Scalable, High-Quality Vector Design and Manufacturing
Viral vectors, especially adeno-associated virus (AAV) and lentivirus (LVV), are essential ex-vivo and in-vivo delivery systems for many advanced therapies, requiring precision engineering, robust GMP manufacturing, and rigorous quality control.
Minaris Viral Vectors supports innovators across every stage of viral vector development — from early research through commercial supply — delivering complete CMC solutions, with product quality at the core.
Our teams bring deep expertise in vector design, process and analytical development, GMP manufacturing and product release and leverage our proprietary platforms and technologies to help therapy developers reduce risk, accelerate timelines, and reach patients faster.
All Viral Vector Services
The success of your program hinges on your process resiliency. Minaris Viral Vectors can partner with you from early construct design to clinical supply, and ultimately commercial GMP production. Our experts integrate process development with proprietary platform technologies to increase yields, enhance consistency, and streamline tech transfer. We offer scalable manufacturing from 50L to 1,000L, supported by a global supply chain network, regulatory-ready documentation, comprehensive analytical testing, and quality systems aligned with international standards.
Learn More
All Viral Vector Technologies
Every program is unique and presents distinct challenges and objectives. At Minaris Viral Vectors, we deliver custom viral vector services tailored to your goals, challenges, and timelines.
Our breakthrough TESSA® technology for scalable AAV production offers flexibility across formats, scales, and process steps — supported by advanced analytics for data-driven decisions. For AAV programs requiring additional optimization, our gene silencing technology can be applied through traditional triple transfection or seamlessly integrated with TESSA®, providing adaptable approaches aligned with your strategic objectives.
We partner with you to unlock the highest yield, titre, and quality, accelerating your path from concept to clinic.
Learn More
Testing Services
With over 40 years of testing experience, our analytical teams will help you design a comprehensive release program for unprocessed bulk, drug substance, and drug product. We offer a complete panel of safety, purity, and identity methods to ensure the final therapeutic product is compliant and ultimately ready for patient delivery. In addition to release assays, Minaris Advanced Testing can also design and execute your drug substance and drug product stability studies or perform characterization assays such as TEM.
Whether your LVV or AAV is intended to be the drug product or an ex vivo gene delivery or editing tool, our team of analytical development experts can optimize and execute your critically important viral potency assays. Our team has years of experience transferring potency assays in-house, optimizing, qualifying, validating, and conducting comparability studies.
Learn MoreViral Vector Technologies
We leverage proprietary technologies to improve the scale, yield, purity, and reliability of AAV and LVV manufacturing. Our platforms—TESSA®, XOFLX®, SnapFast™, off-the-shelf plasmids, and the HEK293 Cell Line—support higher productivity, improved control of starting materials, simplified scale-up, and reduced manufacturing costs compared to traditional transient transfection.
Our plasmid design and engineering expertise helps optimize vector architecture for higher titers, fewer impurities, improved product quality, and faster progression from discovery to IND. These services can be integrated with our platforms or used to enhance existing manufacturing processes.
TESSA®
Scalable, high-yielding AAV production.
XOFLX®
Stable LVV packaging for scalable lentiviral vector manufacturing.
SnapFast™
Plasmid technology supporting faster, more efficient vector workflows.
Off-the-Shelf Plasmids for AAV and LVV Manufacturing
Ready-to-use plasmids that streamline production and accelerate development.
HEK293 Cell line
Clonal suspension cell line with a DMF for scalable viral vector manufacturing.
Explore All
Minaris
Services
Knowledge Center
Explore More Resources
Through our Knowledge Center, we share data-driven insights and best practices from across the industry to help you stay ahead of evolving expectations.
intro-section does not exist
Contact Us
Minaris Viral Vectors is dedicated to helping innovators advance complex viral vector programs with confidence. Whether you are in early stage development or preparing for clinical supply, our vector design expertise, process development capabilities, cGMP manufacturing, integrated testing, and commitment to quality make us a trusted partner for scalable viral vector manufacturing from construct to clinic.
